Abstract:
Embodiments of this disclosure pertain to a vehicle interior system comprising a base having a base surface; and a glass article coupled to the surface, wherein the glass article comprises a first portion comprising a first elastically deformed surface forming a first concave shape with a first radius of curvature from about 20 mm to about 2000 mm, and a second elastically deformed surface directly opposite the first elastically deformed surface that forms a second convex shape, wherein the second elastically deformed surface has a surface compressive stress that is less than a compressive stress at the first elastically deformed surface, and a second portion adjacent the first portion, wherein the second portion is substantially planar portion or curved.
Abstract:
Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.
Abstract:
An electronic device assembly includes a backplane having a glass composition substantially free of alkali ions, an elastic modulus of about 40 GPa to about 100 GPa, and a final thickness from about 20 μm to about 100 μm. The primary surfaces of the backplane are characterized by a prior material removal to the final thickness from an initial thickness that is at least 20 μm greater than the final thickness. The assembly also includes a protect layer on the first primary surface of the backplane; and a plurality of electronic components on the second primary surface of the backplane. In addition, the backplane is configured with at least one static bend having a bend radius between about 25 mm and about 5 mm. The electronic components of the electronic device assembly can include at least one thin film transistor (TFT) element or organic light emitting diode (OLED) element.
Abstract:
The principles and embodiments of the present disclosure relate generally to complexly curved glass articles and methods of cold forming complexly curved glass articles, such as complexly curved glass articles having a first bend region with a set of first bend line segments, and a second bend region with a set of second bend line segments, wherein the first bend line segments and the second bend line segments are independent, are not parallel, and do not intersect.
Abstract:
Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.
Abstract:
Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.
Abstract:
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, NEUPOGEN® (filgrastim), NEULASTA® (pegfilgrastim), (epoetin alfa) or ENBREL® (etanercept).
Abstract:
Embodiments of this disclosure pertain to a vehicle interior system comprising a base having a base surface; and a glass article coupled to the surface, wherein the glass article comprises a first portion comprising a first elastically deformed surface forming a first concave shape with a first radius of curvature from about 20 mm to about 2000 mm, and a second elastically deformed surface directly opposite the first elastically deformed surface that forms a second convex shape, wherein the second elastically deformed surface has a surface compressive stress that is less than a compressive stress at the first elastically deformed surface, and a second portion adjacent the first portion, wherein the second portion is substantially planar portion or curved.
Abstract:
Embodiments of a vehicle interior system are disclosed. In one or more embodiments, the system includes a base with a curved surface, and a display or touch panel disposed on the curved surface. The display includes a cold-bent glass substrate with a thickness of 1.5 mm or less and a first radius of curvature of 20 mm or greater, and a display module and/or touch panel attached to the glass substrate having a second radius of curvature that is within 10% of the first radius of curvature. Methods for forming such systems are also disclosed.
Abstract:
The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, RITUXAN (rituximab), AVASTIN (Bevacizumab), LUCENTIS (Ranibizumab) or HERCEPTIN (trastuzumab).